ty -jour t1-抗木毒胞三烯Zafirlukast在冷空气引起的支气管收缩JF -EUREM ANDIROTARE JORJAN JO -EUR RESSIR J SP -693 LP -699 VL -15 IS -4 AU -RICHTER -RICHTER，KAU -JORORRES，KA au -JORRES，RICHORES，欧洲呼吸杂志JO-，ra au -Magnussen，H Y1-2000/04/01 Ur -http：//www.qdcxjkg.com/content/15/4/4/693.abstract n2-研究的目标是评估效果的幅度白细胞受体拮抗剂Zafirlukast在首次剂量后针对冷空气诱导的支气管收缩，并在给药5天后评估幅度和持续时间。包括19例哮喘患者。在随机交叉设计中，Zafirlukast 20 mg或80 mg B.D.或安慰剂在5天内给予。最后剂量后3小时，在最后剂量后进行了3小时的挑战。作者评估了达到10％（PV10）和20％（PV20）所需的挑衅性通风率，一秒钟内强迫呼气量。Zafirlukast 80毫克的首次剂量的中值PV20 3小时为69.1 l x min-1，而安慰剂为40 l x min-1（p = 0.004）。Zafirlukast 20 mg的相应中值值为59.9 l x min-1（p = 0.06）。在稳定状态下，Zafirlukast 80 mg和安慰剂之间的PV20差异在上次剂量后8小时和12小时显着。 The corresponding difference for zafirlukast 20 mg was statistically significant at 8 h post last dose. The analysis of PV10 yielded compatible results. There was no significant protection 24 h after last dose. This study has demonstrated that zafirlukast offers significant protection against cold air-induced bronchoconstriction in asthma. The degree and duration of protection were dose-dependent. However, there was a large interindividual variability for the protective effect of this leukotriene receptor antagonist. ER -